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Introduction 2 3 Atopic dermatitis (AD) results from a complex interplay of host genetic and environmental 4
factors. There is a long established association between AD and Staphylococcus aureus. In 5 healthy individuals this organism has a dichotomous relationship with the host, being a frequent 6 component of the human microbiome, carried asymptomatically, and on occasion, an 7 opportunistic pathogen capable of causing or influencing a broad ranging disease. In AD, high 8 carriage rates of S. aureus on affected skin is commonly observed, with recent meta-analysis 9 evidence demonstrating colonisation in approximately 70% of affected individuals 1 . High 10 frequency of carriage, and a high colonization burden, have been linked with disease severity in 11 AD. Despite this association, relatively modest advances have been made in understanding if this 12 is causal or consequential. With increasing numbers of microbiome studies it is becoming 13 evident that wider cutaneous microbial imbalances, or dysbiosis, likely contribute to the 14 observed abundance of S. aureus seen in AD, as well as the aetiology of AD. In contrast, 15 antimicrobials, which cause dysbiosis by virtue of their activity, are still used routinely to target 16 S. aureus in the management of this condition. Important questions remain about the extent to 17 which microbiome composition is important in determining the ability of S. aureus to thrive and 18 to drive disease, and the extent to which therapeutic use of antimicrobials may impact on the 19 microbiome and the S. aureus population within it. Against a backdrop of increasing levels of 20 antimicrobial resistance (AMR), careful stewardship of antibiotics is vital to maintain their 21 therapeutic efficacy. In AD, this is of particular concern as S. aureus is an organism that is adept 22 at developing AMR, and also due to the collateral damage that antibiotics inflict on the 23 microbiome. 24
The concept of AD as a microbial diathesis has been a subject of detailed study over the past 26 decade, especially with the advent of 16S rRNA sequencing as a tool to better describe the 27 diversity of the cutaneous bacterial microbiome. Alterations in microbiome composition have 28 been shown to vary in affected individuals compared to healthy controls. People with established 29 AD have overall reduced cutaneous bacterial diversity in comparison to healthy individuals 2 . 30
Specific signature shifts of populations are observed to occur during disease exacerbation, 31 mirroring increasing disease severity, with expansion of staphylococcal populations, primarily S. 32 aureus and S. epidermidis 2 . Development of AD may also be influenced by microbiome 33 composition during infancy, with commensal staphylococci having a protective effect and being 34 significantly less abundant in children who go on to develop AD by 12 months 3 . Presently S. 35 aureus remains the dominant organism in terms of potential contribution to AD pathogenesis. 36
The involvement of S. aureus in disease activity is almost certainly multi-modal, through pro-37 inflammatory interaction by adherence to keratinocytes to secretion of toxins and proteases, 38 reviewed in detail 4 , and illustrated in Figure 1 . At the genetic level, evidence of S. aureus strain 39 association with AD is accumulating. Specific clones of S. aureus are more frequently isolated 40 from diseased skin, than other more widely circulating clones in the general population. This 41 suggests that there may be specific, clonally-associated, properties allowing it to preferentially 42 survive on atopic skin, and drive the pathology of AD 5, 6 . reduce the burden of the organism and its pro-inflammatory effect. Despite lack of robust 72 evidence to support this practice 9 , most dermatologists, allergists and other healthcare providers 73 do so because of a perceived clinical benefit. In milder disease, more frequently seen by non-74 specialists, antibiotic therapy has no benefit over emollients and appropriate strength topical 75 corticosteroids 10 . One potential downside in changing this practice in individuals with greater 76 disease severity is that this patient group is at significantly higher risk of invasive S. aureus 77 infection 11 . Withholding antibiotics in people with more severe AD during disease flares with 78 clinical evidence of infection is therefore clinically difficult to justify, and warrants study to 79 determine if they do indeed improve clinical outcomes when used for severe flares. A 80 confounding and critical issue in this is the lack of universally accepted definitions of 81 colonization versus infection amongst health care providers leading to widely differing 82 thresholds for antibiotic use and indeed overuse. 83 84 Aside from the uncertain benefits of using antimicrobial agents for the management of AD it is 85 important to consider the wider impact of these agents on S. aureus populations associated with 86 AD. Genomic studies have illustrated the role that extensive use of antibiotics has had in 87 generating and maintaining AMR in pathogen populations. The recent history of S. aureus as a 88 pathogen is punctuated by the emergence and spread of AMR clones. The introduction of new 89 antibiotics has invariably been followed shortly after by the appearance of resistant variants in 90 clinical practice; the genetic mechanisms underpinning this resistance are summarised in Figure  91 2. Genomic epidemiological studies have revealed how the widespread use of new antibiotics 92 can drive the epidemic spread of emergent resistant clones 12, 13 . This increasing burden of 93 resistance therefore has specific relevance to practitioners who manage AD in the association with AD in the USA range widely from 6.8% 14 to 45%, 15 while in Europe rates are 104 2% or lower 16, 17 . High prevalence of MRSA in AD drives more frequent use of broader 105 spectrum agents, for instance clindamycin, which in turns drives higher rates of resistance. 106 107 Topical antibiotics pose a particular problem in terms of resistance, outlined in Figure 3 . They 108 are more widely used and are applied with a range of adherence to correct application 109 recommendations, often with sub-therapeutic dosing. These factors likely drive rapid generation 110 of resistance in treated individuals. In Europe, usage of topical fusidic acid (FA) has led to 111 problematic rates of resistance specifically in dermatology, with rates of 40% or more are 112 commonly reported in AD patients, and specific mechanisms of resistance in this population 16,17 . 113 In contrast, FA susceptibility is almost uniform in the USA where the agent is not used. 114
Mupirocin resistance (MupR), conversely, is more prevalent in countries with higher MRSA 115 prevalence. Reported rates from the USA in dermatology patients range from 1.8% to 31.3%, 116
with AD a disease-specific risk factor for carriage of MupR S. aureus 18 Europe, where the agent is generally reserved for MRSA decolonisation therapy, report much 118 lower ranges of MupR associated with AD between 0.7% and 4% 16, 19 . 119 120 Prevalence aside, there is evidence to suggest that MRSA may be associated with greater disease 121 severity. Altered toxin secretion profiles of CA-MRSA strains is one mechanism that has been 122 proposed as an explanation for this 20 . MRSA has a greater effect on displacing cutaneous 123 diversity than methicillin-sensitive S. aureus (MSSA) during AD flares 14 . MRSA has specific 124 effects on corynebacterial and streptococcal species and not on Staphylococcus epidermidis, 125
another staphylococcal component of the skin microbiome. However, overall MRSA 126 colonisation did not correlate with overall disease severity. 14 Antimicrobial usage in general population terms has led to the emergence of multi-drug resistant 144 clones of S. epidermidis globally, worryingly harbouring resistance to last-line glycopeptide 145 antibiotics as well as topical agents such as FA 22 . These examples illustrate that prescribing in 146 AD has the potential to influence wider populations of S. aureus but also the effect that 147 antibiotics may have on other commensals when used in AD. 
